Author name: Kai Chen

Kai is a seasoned finance professional with a quantitative background, uses his broad market experience to provide insightful analysis on the markets, helping investors navigate the complexities of stock trading.

Bulls vs. Bears

Bulls vs. Bears: Kazatomprom’s Production Puzzle & Uranium’s Supply Shortfall

Tune into  this episode of Bulls vs. Bears “Kazatomprom’s Production Puzzle & Uranium’s Supply Shortfall” for an insightful analysis into the challenges facing the uranium market, highlighted by Kazatomprom’s recent production dynamics. Jonathan Tacadena from MPC Markets delves deep into how the world’s leading uranium producer is addressing the growing gap between supply and demand in the global energy sector.

Education

Webinar: Mastering Risk Management

Led by Mark Gardner, our risk management specialist, this session is packed with actionable insights designed to help you stabilize your investment journey and navigate the markets with renewed confidence. From personal risk tolerance to strategic company and market risk assessments, you’re in for a comprehensive guide to tailoring your investment approach.

Balanced Portfolio

Balanced Portfolio Recommendation: Buy 1.5% Liontown Resources Ltd (LTR) & Buy 2% Mineral Resources Ltd MIN

It’s been a rocky ride for Lithium so far this year but through all the noise, we see quality buying opportunities in the space for the long term. Mining giants Gina Rinehart and Chris Ellison have long track records in running profitable mining operations in literally the most abundant mineral on the planet, Iron Ore and they are aggressively buying into the next mining boom of Lithium.

Balanced Portfolio

Balanced Portfolio Recommendation: Switch 2% ResMed (RMD) to Clinuvel Pharmaceuticals Ltd (CUV)

With the recent run in RMD we are looking to bank some profits here at $29 (+20%) while we see further upside in the stock, the risk that further developments in the GLP-1 space could derail this recent run. Particularly a study due from Eli Lily a maker of Zepbound in the next month.

We still prefer exposure in the healthcare space and are recommending a switch of our RMD allocation to Clinuvel (CUV) a skin disease treatment for sufferers of EPP. They are also in Phase 2 of a stroke treatment drug which is looking promising 

Scroll to Top